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ABSTRACT 
Importance: Minimally Invasive Glaucoma Surgery has gained significant traction in recent 
years. This study evaluates the first and second-generation trabecular micro-bypass stents 
‘iStent’ and ‘iStent inject’. 
Background: To evaluate and compare the effect of a single iStent and double iStent inject 
in Primary Open Angle Glaucoma. 
Design: Prospective comparative case series. 
Participants: Primary Open Angle Glaucoma patients undergoing trabecular micro-bypass 
stent insertion combined with cataract surgery. 
Methods: Baseline demographic information, pre-operative, intra-operative and post-
operative outcomes including intraocular pressure (IOP), visual acuity, reliance on glaucoma 
medication and complications were collected and analysed. 
Main Outcome Measures: Primary, secondary and tertiary outcome measures were 
consecutively defined as an IOP of ≤ 18mmHg with zero medications, an IOP of ≤ 18mmHg 
with reduced medications or a 20% reduction in IOP with or without medication. 
Results: The study comprised 145 eyes in the iStent and 100 eyes in the iStent inject group. 
At 12 months, 56.0% of the iStent and 51.3% of the iStent inject eyes had achieved primary 
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success and 63.1% and 57.7% secondary success. The mean post-operative IOP was 
16.6mmHg in iStent and 16.9mmHg in iStent inject. Survival analysis demonstrated a greater 
incidence of failure in the iStent inject beyond 5 months. 
Conclusions: Both trabecular micro-bypass stents in this study were effective in reducing 
IOP and the burden of medication when combined with cataract surgery. There was no 
statistically significant difference between the two groups across our outcome measures 
although the iStent inject required earlier recommencement of medications for optimal IOP 
control. 
Introduction 
Minimally Invasive Glaucoma Surgery (MIGS) has gained significant traction over the past 
few years. New devices and procedures are constantly being developed in an effort to lower 
intraocular pressure (IOP) in a less invasive and purportedly safe manner. In Australia, there 
has been a marked increase in MIGS uptake with Medicare data indicating an exponential 
increase in use over the last few years.1, 2 Although MIGS is currently seen primarily as 
adjunct to cataract surgery, it is increasingly being considered as a viable initial treatment 
option.3 
The objective of this study was to evaluate and compare the first and second-generation 
trabecular micro-bypass stents, ‘iStent’ and ‘iStent inject’ (Glaukos Corporation, CA, USA). 
Trabecular stent bypass microsurgery aims to reduce intraocular pressure by creating a 
bypass channel between the anterior chamber and Schlemm’s canal to improve the drainage 
of aqueous humour.  iStent was the first ab-interno micro-bypass device of its kind based on 
this principal. The 1mm long, L-shaped titanium device is implanted via a preloaded injector 
through the trabecular meshwork under gonioscopic guidance. Once inside the trabecular 
meshwork, a well placed stent provides aqueous outflow directly into collector channels. 
 3 
Figure 1 A. First generation trabecular micro-bypass stent (iStent). B. Second generation 
trabecular micro-bypass stent, (iStent inject). Image supplied. 
 
Although successful in reducing the IOP, the iStent was superseded by iStent inject, a much 
smaller second generation trabecular micro-bypass stent. The iStent inject is a 0.4mm long, 
0.3mm wide plug shaped implant with a central opening that is injected into the trabecular 
meshwork under gonioscopic guidance. The stent was redesigned for easier insertion and its 
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injector is pre-loaded with two stents inserted approximately 2 to 3 clock hours away from 
each other. (Figure 1) 
A number of studies have demonstrated the effectiveness of iStent and iStent inject. In a 
systematic review and meta-analysis of 2,143 patients from 32 studies, comparing stent 
insertion combined with phacoemulsification against phacoemulsification alone in patients 
with glaucoma and cataract, there was a statistically significant decrease in IOP from baseline 
in the combined group compared with the phacoemulsification only group at a follow up of 
12- 58 months.4 The meta-analysis also demonstrated a significant reduction in the number of 
glaucoma medications used after the procedure in the combined group compared with the 
phacoemulsification only group (weighted mean reduction of 1.33 from baseline compared 
with 1.01).4 Significant reduction in IOP from baseline has also been demonstrated in patients 
with mild to moderate glaucoma treated with stent insertion alone at follow up of 6-18 
months.5 
Although each trabecular micro-bypass device has proven to be efficacious, the two devices 
have not been previously compared in performance and efficacy. 
Methods 
Study design 
We conducted a prospective comparative case series on patients with mild to moderate 
primary open angle glaucoma (POAG) and cataracts. Patients undergoing cataract surgery 
combined with stent insertion were consecutively recruited from two centres across 
Launceston, Tasmania, Australia. Mild to moderate POAG was defined as having a vertical 
cup to disc ration of 0.8 or less with stable serial IOPs and visual field assessments. All 
patients were seen and operated on by a single senior glaucoma specialist with extensive 
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experience in trabecular stent micro-bypass surgery. iStent was considered well placed when 
only the "snorkel" component was visible with the rest of the implant inside the Schlemm’s 
canal. iStent inject was considered well placed when the level of the "collar" was flush with 
the trabecular meshwork. The study was conducted in accordance with the tenets of the 
Declaration of Helsinki; ethics approval was obtained from the University of Tasmania 
Human Research Ethics Committee (H0014226). 
Baseline demographic information as well as data on IOP, visual acuity and reliance on the 
number of glaucoma medications were recorded pre and post operatively. Intraoperative 
observations on device performance and complications were made. Patients were seen at day 
1 and week 3-4 post operative at which point all glaucoma medications were ceased. The 
post-operative steroid regime was kept identical between the two groups. Follow up occurred 
every 3 months or as otherwise clinically indicated. Patients were recommenced on 
monotherapy if IOP was greater than 18mmHg in any follow up visit; an IOP of 18mmHg 
was chosen as it has been shown to reduce the long term progression of visual field defects.6 
Further agents were added one at a time at each follow up if clinically indicated. A cut off of 
18 months was chosen as very few patients had passed this milestone in the second 
generation device, iStent inject, group. 
Outcome measures 
• Primary success was defined as an IOP of 18mmHg or less with zero number of 
topical glaucoma medications.  
• Secondary outcome was defined as an IOP of 18mmHg or less with reduced number 
of topical glaucoma medications.  
• Tertiary outcome was defined as a 20% reduction in IOP with or without topical 
glaucoma therapy. 
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Statistical analysis 
Patient data entered into Excel (Microsoft Inc, WA, USA) were extracted and imported into 
Stata 15 (StataCorp LLC, TX, USA) for analysis. Numbers of eyes and percentages are 
reported for categorical data and means with standard deviations for continuous data. Cross-
tabulations were produced to compare categorical data in the iStent and iStent inject groups, 
with chi-square tests used to evaluate statistically significant differences. Independent t-tests 
were used to investigate mean IOP, number of glaucoma medications and visual acuity 
(logMAR) comparison in the iStent and iStent inject groups. A Kaplan-Meier survival curve 
was plotted for time to glaucoma medication re-initiation after surgery within 18 months of 
follow-up and median time to drop re-initiation was calculated. 
Results 
The study comprised 245 eyes from 148 patients, aged 53-89 years at the time of the 
operation (Mean 71, SD 7.1). There were 145 eyes in the iStent and 100 eyes in iStent inject 
groups. All patients had a confirmed diagnosis of POAG. The mean pre-operative IOP was 
identical in both groups (18.9mmHg). The mean pre-operative number of topical agents was 
1.7 in the iStent and 1.6 in the iStent inject group. Patient demographics and baseline 
characteristics are shown in table 1. 
Table 1. Patient demographics and baseline characteristics 
 Mean (SD) or n (%)  
Variable Both iStent iStent inject P value 
Eyes (n) 245 145 100 -  
Right (n) 120 (49.0) 73 (50.3) 47 (47.0) 0.61 
Age (years) 71 (7.1) 70.2 70.9 0.40 
Gender (female) 135 (55.3) 87 (60.4) 48 (48.0) 0.06 
Pre-operative IOP (mmHg) 18.9 (5.2) 18.9 (4.7)  18.9 (5.9) 0.93 
Pre-operative agents (n) 1.6 (0.1) 1.7 (0.1) 1.6 (0.1) 0.64 
Pre-operative visual acuity (logMAR) 0.2 (0.1) 0.2 (0.1) 0.1 (0.1) 0.28 
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(Snellen equivalent) 9.5 9.5 7.5 - 
IOP = intraocular pressure 
 
Outcome measures 
At 12 months, 56.0% of the iStent and 51.3% of the iStent inject eyes had achieved primary 
success and 63.1% and 57.7% secondary success. Tertiary success was achieved in 34.8% in 
the iStent and 29.5% in the iStent inject eyes. Forty-three eyes reached 18 months of follow 
up in the iStent inject group due to later introduction of the device. The main outcome 
measures achieved at different time points across the study are outlined in table 2. 
 
Intraocular pressure 
Table 2. Primary, Secondary and Tertiary outcome comparison 
Time (Months) Both iStent iStent inject P value 
 Primary Success n (%) 
  3 158 (67.8) 93 (67.4) 65 (68.4) 0.87 
 6 148 (63.2) 94 (65.3) 54 (60.0) 0.42 
12 119 (54.3) 79 (56.0) 40 (51.3) 0.50 
18 84 (47.5) 65 (48.5) 19 (44.2) 0.62 
 Secondary Success n (%) 
  3 164 (70.4) 98 (71.0) 66 (69.5) 0.80 
 6 161 (68.8) 105 (72.9) 56 (62.2) 0.09 
12 134 (61.2) 89 (63.1) 45 (57.7) 0.43 
18 102 (57.6) 81 (60.4) 21 (48.8) 0.18 
 Tertiary Success  n (%) 
  3 88 (37.8) 51 (37.0) 37 (38.9) 0.76 
 6 67 (28.6) 42 (29.2) 25 (27.8) 0.82 
12 72 (32.9) 49 (34.8) 23 (29.5) 0.43 
18 67 (37.9) 51 (38.1) 16 (37.2) 0.92 
N = number; % = percentage; Total number of eyes for both groups n = 233 at 3 months, 234 at 6 months, 
219 at 12 months and 177 at 18 months. There were 43 eyes that reached 18 months follow up in the iStent 
inject group. 
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Figure 2 depicts the mean IOP for the iStent and iStent inject groups pre-operatively and at 
each follow-up timepoint. For each timepoint, there was no significant difference in mean 
IOP between the groups. The mean IOP was generally reduced over the study period however 
an uptrend was noted in the iStent inject eyes from 6 months following surgery. Raw IOP 
data pre-operatively compared with 12 months post-operative are shown in Figure 3. 
 
 
Figure 2. Error bar graphs demonstrating the mean IOP trend in iStent (top) and iStent inject 
(bottom). 
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Figure 3. Scatter plot graph of the raw IOP data pre-operatively compared with 12 months 
post-operative for iStent and iStent inject eyes. Data points above the line indicate a reduction 
in IOP, those on the line indicate no change with those below the line indicating an increase 
in post-operative IOP. 
Glaucoma medication 
The mean number of glaucoma medications used reduced from 1.7 to 0.6 in the iStent group 
and 1.6 to 0.7 in iStent inject eyes. An overview of the reduction in the mean number of the 
glaucoma medications used is demonstrated in Figure 4. The number of eyes and the 
distribution of the number of glaucoma agents required in the pre-operative compared with 
the post-operative period is demonstrated in Figure 5. 
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By 12 months, 90 of the 141 (63.8%) iStent and 52 of the 79 (66.7%) iStent inject eyes had 
recommenced topical glaucoma therapy. Of those who required recommencement of topical 
therapy, the mean time to drop initiation was 12 months for iStent and 7 months for iStent 
inject. Overall, 49% of the eyes did not require topical therapy during the follow up period. 
 
Figure 4. Mean number of glaucoma agents used over 18 months. 
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Figure 5. Number of eyes (y axis) and the distribution of the number of glaucoma agents (x 
axis) required in the pre-operative (bottom) compared with the post-operative (top) period. 
 
A very similar survival experience (estimated time to topical therapy initiation post surgery) 
was demonstrated in both groups for up to 5 months post-operative utilising the Kaplan – 
Meier survival estimator. From 5 months on, the survival curves begin to diverge, with the 
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greater incidence of failure (defined as the initiation of eye drops) in the iStent inject eyes 
(Figure 6). 
 
Figure 6. Kaplan-Meier survival analysis demonstrating time to post-operative initiation of 
glaucoma medications. 
 
Visual acuity 
The mean best corrected visual acuity at 12 months was 0.09 logMAR (SD 0.11) or 6/7.5 
Snellen equivalent, with no significant difference between the two groups (t (188) = -0.8, p = 
0.41).  
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Hyphaema was the most common complication observed with higher incidence in the iStent 
eyes. These were conservatively managed with no further complications. Corneal abrasions, 
corneal oedema, implant failure and stent malposition made up the remainder of the small 
number of complications observed (Table 3.)  Only 1 patient implanted with iStent inject, 
presented with a delayed spontaneous non-traumatic macro-hyphaema 4 months post implant 
insertion. This was conservatively managed and resolved without further complications. 
Table 3.  Complications  
  Complication iStent [n = 145] iStent inject [n = 100] P value 
In
tra
 - 
  
op
er
at
iv
e 
Bleeding in AC 13 (8.9%) 4 (4.0%) 0.13 
Corneal abrasion 3 (2.1%) 0 0.27 
Failure to implant 1 (0.7%) 0 1.00 
Failure to implant 2 stents N/A 2 (2.0%) N/A 
Stent malposition 3 (2.1%) 1 (1.0%) 0.65 
Ea
rly
 P
os
t  
 o
pe
ra
tiv
e 
Hyphaema 14 (9.7%) 6 (6.0%) 0.35 
Corneal oedema 3 (2.1%) 1 (1.0%) 0.65 
Corneal abrasion 1 (0.7%) 1 (1.0%) 1.00 
AC = anterior chamber; NA = not applicable 
 
Discussion 
The first and the second generation trabecular micro-bypass stents are both proven to be 
efficacious in reducing IOP and reliance on glaucoma medications in mild to moderate 
glaucoma. Despite the relative ease in intraoperative insertion of these implants under 
gonioscopic guidance, these ab-interno micro-stents are subject to intraoperative 
malpositionning which can result in failure of implantation or luminal obstruction and 
decreased efficacy.7, 8 The 1mm long, L shaped first generation device, iStent, is slightly 
more difficult to implant owing to its size and shape. Higher incidence of intraoperative 
hyphaema is also reported with occasional recurrence and lumen blockage requiring implant 
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removal.9-11 The second generation device, iStent inject, is a much smaller implant at 0.4mm 
long and was specifically designed for ease of insertion. The iStent inject’s pre-loaded 
injector is also equipped with 2 implants usually utilised at the same time, thereby reducing 
the impact of single implant blockage. 
Our results confirm the efficacy of each stent consistent with other published literature to 
date. In a randomised controlled clinical evaluation of the trabecular micro-bypass stent 
(iStent) with phacoemulsification in patients with glaucoma and cataract 72% achieved 
primary outcome success.12 The nominated IOP to recommence treatment in this study was 
however set higher at 21mmHg. We elected for a more conservative approach and chose to 
recommence treatment at 18mmHg based on evidence from the Advanced Glaucoma 
Intervention Study (AGIS).6 Interestingly 50% of the control eyes in the randomised 
controlled trial achieved an IOP of less than 21mmHg following cataract surgery alone.12 
Our study found 56.0% primary success at 12 months in the iStent group and 51.3% in the 
iStent inject group. Given the small difference between the groups, a post-hoc power 
calculation found more than 1500 patients would need to be recruited to each group to detect 
a significant difference at 80% power and α = 0.05. This suggests a true null difference 
between the groups in the proportion of eyes achieving primary success at 12 months. 
We compared the effects of both stents in a prospective study of POAG patients with very 
similar if not identical demographics and baseline characteristics. Although there were no 
statistically significant differences between the two groups across our outcome measures, we 
noted iStent inject patients require earlier recommencement of topical glaucoma therapy for 
optimal IOP control. We postulate this to be due to the dynamics of fluid flow through the 
stent lumen with the iStent having a larger drainage pathway than that of the iStent inject. 
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The higher incidence of complications associated with iStent observed in our cohort are 
statistically not significant and had no bearing on our patients’ final visual outcomes. 
Conclusion 
Both trabecular micro-bypass stents in this study reduced IOP by a mean of 2.0 – 2.3mmHg 
and reduced the mean number of medications by 0.8 to 1.0 . There was no statistically 
significant difference between the two groups across our outcome measures. Both devices 
appear to be safe with no significant visual or IOP related complications. 
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